Title: | Addiction, Vol.113, n°8 - August 2018 |
Publication Date: | 2018 |
Descriptors: |
SANTEPSY ABSTINENCE ; ACHAT ; ACTION COMMUNAUTAIRE ; ADDICTION ; ALCOOL ; BACLOFENE ; BUPRENORPHINE ; COHORTE ; COMPARAISON ; COMPULSION ; DEPISTAGE ; EFFET SECONDAIRE ; EFFICACITE ; EPIDEMIOLOGIE ; EPIDEMIOLOGIE DESCRIPTIVE ; INTERVENTION ; INTOXICATION ; LEGISLATION ; METHADONE ; METHODE ; MILIEU FESTIF ; MORTALITE ; PREVENTION ; QUESTIONNAIRE ; REDUCTION DE CONSOMMATION ; TEST ; TRAITEMENT ; TRAITEMENT DE SUBSTITUTION |
Abstract: |
CONTENTS: - What role does dopamine really play in tobacco addiction? [Editorial]. Chiamulera C., West R.J., p. 1379-1380. - Introduction to a new series on case studies on the addiction policy process. Holmes J., p. 1381. - Evaluating clinical stop-smoking services globally: towards a minimum data set [Addiction debate]. Skinner A.L., West R., Raw M., Anderson E., Munafo M.R., p. 1382-1389. - Tobacco cessation in low- and middle-income countries: some challenges and opportunities. Peer N., Kengne A.P., p. 1390-1391. - Expanding smoking cessation world-wide. Jha P., p. 1392-1393. - Recommendations for linking client data with clinic services to improve our ability to make inferences. Pearson J.L., Villanti A.C., p. 1393-1395. - Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Rose A.K., Jones A., p. 1396-1406. - Treatment response and non-response in CBT and Network Support for alcohol disorders: targeted mechanisms and common factors. Litt M.D., Kadden R.M., Tennen H., p. 1407-1417. - Commentary on Litt et al. (2018): Identifying treatment-targeted mechanisms-aim and measure the bullseye. Kiluk B.D., p. 1418-1419. - Drink Less Enjoy More: effects of a multi-component intervention on improving adherence to, and knowledge of, alcohol legislation in a UK nightlife setting. Quigg Z., Hughes K., Butler N., Ford K., Canning I., Bellis M.A., p. 1420-1429. - Attempts to reduce alcohol intake and treatment needs among people with probable alcohol dependence in England: a general population survey. Dunne J., Kimergard A., Brown J., Beard E., Buykx P., Michie S., et al., p. 1430-1438. - Trajectory classes of cannabis use and heavy drinking among rural African American adolescents: multi-level predictors of class membership. Barton A.W., Brody G.H., Zapolski T.C.B., Goings T.C., Kogan S.M., Windle M., et al., p. 1439-1449. - An investigation of an open-access model for scaling up methadone maintenance treatment. Madden L.M., Farnum S.O., Eggert K.F., Quanbeck A.R., Freeman R.M., Ball S.A., et al., p. 1450-1458. - Commentary on Madden et al. (2018): 'It's not only about the destination... it's also about the journey!' Consumer perspectives on a model of open-access MAT provision. Madden A., p. 1459-1460. - The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Hickman M., Steer C., Tilling K., Lim A.G., Marsden J., Millar T., et al., p. 1461-1476. - Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Saxon A.J., Akerman S.C., Liu C.C., Sullivan M.A., Silverman B.L., Vocci F.J., p. 1477-1487. - Associations between personality disorders and cannabis use and cannabis use disorder: a population-based twin study. Gillespie N.A., Aggen S.H., Neale M.C., Knudsen G.P., Krueger R.F., South S.C., et al., p. 1488-1498. - A survey of tobacco dependence treatment guidelines content in 61 countries. Nilan K., McNeill A., Murray R.L., McKeever T.M., Raw M., p. 1499-1506. - Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. West R., Evins A.E., Benowitz N.L., Russ C., McRae T., Lawrence D., et al., p. 1507-1516. - Four-year follow-up of an internet-based brief intervention for unhealthy alcohol use in young men. Bertholet N., Studer J., Cunningham J.A., Gmel G., Burnand B., Daeppen J.B., p. 1517-1521. - Methamphetamine psychosis: insights from the past. McKetin R., p. 1522-1527. - Can one simple questionnaire assess substance-related and behavioural addiction problems? Results of a proposed new screener for community epidemiology. Schluter M.G., Hodgins D.C., Wolfe J., Wild T.C., p. 1528-1537. - Commentary on Schluter et al. (2018): Revisiting the core elements of addiction using a lay epidemiology approach. Gonzalez-Saiz F., p. 1538. - Using the Advocacy Coalition Framework and Multiple Streams policy theories to examine the role of evidence, research and other types of knowledge in drug policy. Ritter A., Hughes C.E., Lancaster K., Hoppe R., p. 1539-1547. - Commentary on Ritter et al. (2018): Making research active in policy-engaging in ontological politics and evidence events. Dilkes-Frayne E., p. 1548-1549. - Access to medical cannabis is expanding across North America regardless of the opioid crisis-why not study if it could help? Lake S., Milloy M.J., p. 1550-1551. - Cannabis and opioid overdoses: time to move on and examine potential mechanisms. Rogeberg O., Blomkvist A.W., Nutt D., p. 1551-1552. - An experimental method for assessing whether marijuana use reduces opioid use in patients with chronic pain. Darnall B.D., Humphreys K.N., p. 1552-1553. - The need for more consistent evidential standards in cannabis policy evaluations. Hall W., West R., Marsden J., Humphreys K., Neale J.O., Petry N., p. 1553-1554. |
Copies (1)
Location | Call number | Emplacement | Media type | Section | Status |
---|---|---|---|---|---|
Hôpital Marmottan | Abonnement | Hôpital Marmottan | Périodique | Généralités | Available |